Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

The aim of this review is to report on the current status of prostate-specific membrane
antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68 Ga …

The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …

Background Prostate cancer is radiosensitive. Prostate‐specific membrane antigen (PSMA)
is selectively overexpressed on advanced, castration‐resistant tumors. Lutetium‐177 …

Purpose: Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide
therapy of metastatic castration-resistant prostate cancer (mCRPC). PSMA-targeted alpha …

Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-
emitting 177 Lutetium has already been investigated in several early phase dosimetry …

Alpha-emitters are radionuclides that decay through the emission of high linear energy
transfer α-particles and possess favorable pharmacologic profiles for cancer treatment …

The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic
strategies. Prostate tumors specifically express the prostate‐specific membrane antigen …

Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation
are locally delivered to tumor cells, while the surrounding healthy tissue is minimally …